Literature DB >> 10504699

Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment.

M Birchler1, F Viti, L Zardi, B Spiess, D Neri.   

Abstract

Molecules that selectively target and occlude new blood vessels would be useful for diagnosis and treatment of pathologies associated with angiogenesis. We show that a phage-derived human antibody fragment (L19) with high affinity for the ED-B domain of fibronectin, a marker of angiogenesis, selectively localizes to newly formed blood vessels in a rabbit model of ocular angiogenesis. The L19 antibody, chemically coupled to a photosensitizer and irradiated with red light, mediates complete and selective occlusion of ocular neovasculature and promotes apoptosis of the corresponding endothelial cells. These results demonstrate that new ocular blood vessels can be distinguished immunochemically from preexisting ones and suggest that the targeted delivery of photosensitizers may be effective in treating angiogenesis-related pathologies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10504699     DOI: 10.1038/13679

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  17 in total

Review 1.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

2.  Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.

Authors:  Patrizia Castellani; Laura Borsi; Barbara Carnemolla; Attila Birò; Alessandra Dorcaratto; Giuseppe L Viale; Dario Neri; Luciano Zardi
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

3.  Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening.

Authors:  L Giovannoni; F Viti; L Zardi; D Neri
Journal:  Nucleic Acids Res       Date:  2001-03-01       Impact factor: 16.971

4.  Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration.

Authors:  Puran S Bora; Zhiwei Hu; Tongalp H Tezel; Jeong-Hyeon Sohn; Shin Goo Kang; Jose M C Cruz; Nalini S Bora; Alan Garen; Henry J Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-14       Impact factor: 11.205

5.  Bioconjugatable porphyrins bearing a compact swallowtail motif for water solubility.

Authors:  K Eszter Borbas; Pawel Mroz; Michael R Hamblin; Jonathan S Lindsey
Journal:  Bioconjug Chem       Date:  2006 May-Jun       Impact factor: 4.774

6.  Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer.

Authors:  Zhiwei Hu; Benqiang Rao; Shimin Chen; Jinzhong Duanmu
Journal:  Breast Cancer Res Treat       Date:  2010-06-01       Impact factor: 4.872

7.  Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice.

Authors:  Zhiwei Hu; Benqiang Rao; Shimin Chen; Jinzhong Duanmu
Journal:  BMC Cancer       Date:  2010-05-26       Impact factor: 4.430

8.  Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics.

Authors:  Leanne B Josefsen; Ross W Boyle
Journal:  Theranostics       Date:  2012-10-04       Impact factor: 11.556

9.  Development and characterization of novel photosensitizer : scFv conjugates for use in photodynamic therapy of cancer.

Authors:  Chrysovalanto Staneloudi; Karen A Smith; Robert Hudson; Nela Malatesti; Huguette Savoie; Ross W Boyle; John Greenman
Journal:  Immunology       Date:  2007-04       Impact factor: 7.397

10.  Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.

Authors:  Kathrin Schwager; Manuela Kaspar; Frank Bootz; Roberto Marcolongo; Erberto Paresce; Dario Neri; Eveline Trachsel
Journal:  Arthritis Res Ther       Date:  2009-09-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.